2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago — CAMBRIDGE, Mass., September 25, 2024 -- (BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago — 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in …
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In …
WEB2 days ago — 2seventy bio, Inc (NASDAQ: TSVT) and its partner Bristol Myers Squibb & Co (NYSE: BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel;...
Struggling 2Seventy scraps a key cancer study | BioPharma Dive
WEB3 days ago — 2Seventy bio, the cancer-focused drugmaker spun out of Bluebird bio, has decided to stop enrolling a key study that’s been evaluating its multiple myeloma therapy Abecma earlier in the treatment process.
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB3 days ago — 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study. Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025
2seventy bio Announces New Strategic Path Forward
WEBJan 30, 2024 — CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 30, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma.
2seventy bio Announces Completion of Oncology and …
WEBApr 1, 2024 — Going forward, 2seventy bio will focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS).
2seventy bio Completes Spin Transaction and Launches …
WEBNov 4, 2021 — 2seventy bio, Inc., (NASDAQ: TSVT), an emerging immuno-oncology company today announced its official launch as an independent, publicly traded company.
2seventy, Bristol Myers Discontinue Enrollment In Phase 3
WEB2 days ago — (RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment in Phase 3 KarMMa-9 study evaluating Abecma with...
2seventy bio
WEB2seventy bio’s heritage is anchored in deep care for patients and our people, thought leadership, and scientific expertise from our gene therapy and oncology roots. The company was spun out of bluebird bio, Inc., a pioneer in gene and cell therapy.